Is Carmell Corp. overvalued or undervalued?

As of 31 March 2025, the valuation grade for Carmell Corp. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently overvalued, given its negative P/E ratio and other concerning metrics. Key ratios include a Price to Book Value of -0.72, an EV to EBIT of -0.43, and an EV to EBITDA of -0.45, all of which reflect the company's struggles.
In comparison to its peers, Carmell Corp. shows a less favorable position, with its EV to EBITDA ratio of -0.4545 compared to Immunome, Inc. at -2.5424 and CARA Therapeutics, Inc. at -8.0086, both of which are also classified as risky. The company's stock performance has been dismal, with a year-to-date return of -67.87%, contrasting sharply with the S&P 500's modest gain of 2.44%. This further reinforces the notion that Carmell Corp. is not only overvalued but also facing significant operational challenges.